Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.

A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.

Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.

In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.

In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.

Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.